Coulter Partners secures Chief Commercial Officer for Nanoform
Coulter Partners was delighted to partner with Helsinki-based drug particle engineering and nanotechnology company, Nanoform to secure the appointment of Christian Jones as Chief Commercial Officer. The newly created role is imperative for developing a commercial strategy to catapult Nanoform’s novel nanonization technology into the global pharmaceutical marketplace.
International commercialization is the next step for establishing Nanoform as a revolutionary technology provider for Pharma and Biotech companies. Its proprietary nanonization services can significantly reduce rates of clinical attrition through improved drug solubility and bioavailability.
Christian Jones has international business development and commercial experience within both pharmaceutical, and biotechnology industries, specifically in the particle engineering and drug delivery fields. His extensive global networks will be used to connect drug developers with Nanoform’s technological solutions. He joins Nanoform from Johnson Matthey Plc, where he was Commercial Director for European API development and manufacturing, having previously held senior commercial roles at Dr Reddy’s Laboratories Ltd. and Prosonix Ltd.
The appointment comes at a pivotal time in Nanoform’s growth, having recently completed a EUR 7m funding round for investment in its technology and talent hiring. The role of Chief Commercial Officer will be fundamental for the initial 18-month strategy to increase international sales and globalize the particle engineering technology, and for the subsequent company growth beyond this.
Commenting on the appointment, Edward Hæggström, Nanoform’s CEO, said: “I am delighted to welcome Christian to Nanoform and thank the Coulter Partners team for their outstanding work on our behalf in achieving this quality appointment. Christian’s solid experience and understanding of the pharmaceutical markets, in combination with his knowledge in commercializing proprietary particle engineering technology, will be invaluable to developing Nanoform’s global business development strategy.”
Christian Jones added: “I am very excited to be joining the Nanoform team at such an exciting time for the business. Nanoform has developed a ground-breaking technology and I am delighted to be a part of this new particle engineering story in the marketplace.”
Nanoform Finland Limited is an innovative drug particle engineering and nanotechnology company that provides novel API particle-size reduction services, helping to de-risk drug development projects in the pharmaceutical pipeline. We work together with international pharma to give failed molecules a second chance in the drug development pipeline through our best-in-class nanonization services. Our multi-patented Controlled Expansion of Supercritical Solutions (CESS) technology uses supercritical carbon dioxide to reduce API particle size homogeneously. This unique technology precisely alters the physical properties of a drug to significantly optimise therapeutics through an enhanced dissolution rate and improved bioavailability.
For more information please visit http://www.nanoform.fi/